<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style="text-align: left"&gt;DEPARTMENT OF HEALTH AND HUMAN SERVICES&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;Food and Drug Administration&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;[Docket No. &lt;span&gt;FDA-2011-N-0002]&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;a name="OLE_LINK1"&gt;&lt;span&gt;General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;AGENCY:&amp;nbsp;Food and Drug Administration, HHS.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;ACTION:&amp;nbsp;Notice.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA).&amp;nbsp;The meeting will be open to the public.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;u&gt;Name of Committee&lt;/u&gt;: General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;u&gt;General Function of the Committee&lt;/u&gt;:&amp;nbsp;To provide advice and recommendations to the Agency on FDA's regulatory issues.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;u&gt;Date and Time&lt;/u&gt;:&amp;nbsp;The meeting will be held on April 27, 2011, from 8 a.m. to 6 p.m.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;u&gt;Location&lt;/u&gt;: Holiday Inn, Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;u&gt;Contact Person&lt;/u&gt;: Margaret McCabe-Janicki, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1535, Silver Spring, MD 20993, 301-796-7029, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area.&amp;nbsp;Please call the Information Line for up-to-date information on this meeting.&amp;nbsp;A notice in the &lt;u&gt;Federal Register&lt;/u&gt; about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.&amp;nbsp;Therefore, you should always check the Agency&amp;rsquo;s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;u&gt;Agenda&lt;/u&gt;:&amp;nbsp;On April 27, 2011, the committee will discuss, make recommendations, and vote on information related to the premarket approval application supplement for RESTYLANE, sponsored by Medicis Aesthetics, Inc.&amp;nbsp;RESTYLANE is currently approved for mid- to deep-dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.&amp;nbsp;The sponsor is requesting an expanded indication, to include use of RESTYLANE for augmentation of the lips.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting.&amp;nbsp;If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&amp;nbsp;Background material is available at &lt;u&gt;&lt;a href="http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm"&gt;&lt;font color="#800080"&gt;http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm&lt;/font&gt;&lt;/a&gt;&lt;/u&gt;. Scroll down to the appropriate advisory committee link.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;u&gt;Procedure&lt;/u&gt;:&amp;nbsp;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&amp;nbsp;Written submissions may be made to the contact person on or before April 19, 2011.&amp;nbsp;Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on the meeting day.&amp;nbsp;Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before April 8, 2011.&amp;nbsp;Time allotted for each presentation may be limited.&amp;nbsp;If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.&amp;nbsp;The contact person will notify interested persons regarding their request to speak by April 12, 2011.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact AnnMarie Williams, Conference Management Staff, 301-796-5966, at least 7 days in advance of the meeting.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;FDA is committed to the orderly conduct of its advisory committee meetings.&amp;nbsp;Please visit our Web site at &lt;u&gt;&lt;a href="http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm"&gt;http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm&lt;/a&gt;&lt;/u&gt; for procedures on public conduct during advisory committee meetings.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;Dated: &lt;u&gt;March 11, 2011&lt;/u&gt;.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;Leslie Kux,&lt;/div&gt;&lt;div style="text-align: left"&gt;Acting Assistant Commissioner for Policy.&lt;/div&gt;</wcm:element>
</wcm:root>
